1.Analysis and forecast of burden of pancreatic cancer along with attributable risk factors in Asia countries between 1990 and 2019.
Dong Yu CHEN ; Xiao Yu YANG ; Wen Long FAN ; Hong Xin WANG ; Pu WANG ; Min HU ; Su Yue PAN ; Qiao HUANG ; Yu Qing HE
Chinese Journal of Oncology 2022;44(9):955-961
Objective: To analyze the disease burden of pancreatic cancer in major Asian countries and forecast the burden of that in China, which helps to provide reference for the prevention and control of pancreatic cancer. Methods: Data on disease burden of pancreatic cancer among global and major Asian countries from on the Global Burden of Disease (GBD) 2019 were collected to describe burden distribution through the absolute numbers or standardized rates of incidence, death and disability adjusted life years (DALY) by year, sex and socio-demographic index. Estimated annual percentage changes (EAPC) was used to assess the trend of standardized rate. The proportion of deaths attributable to risk factors for pancreatic cancer in 2019 was used to compare by age, sex and region. ARIMA model was performed with R language to predict change of age-standardized incidence and death rates of pancreatic cancer from 2020 to 2029. Results: From 1990 to 2019, the standardized incidence rates of pancreatic cancer in China increased from 3.17/100 000 to 5.78/100 000, and the standardized death rate increased from 3.34/100 000 to 5.99/100 000. The increases exceeded other high-income Asia countries. In the past three decades, the standardized incidence, death and DALY rates of pancreatic cancer in global have increased year by year. Among the major countries in Asia, China has the highest growth rate of disease burden (EAPC of standardized incidence rates=2.32%, 95% CI: 2.10%-2.48% and EAPC of standardized death rate=2.25%, 95% CI: 2.03%-2.42%). In addition, incidence and death rates of pancreatic cancer in China are expected to continue on the rise between 2000 and 2029 by ARIMA model. Incidence rate is expected to increase 15.92% and death rate is expected to increase 15.86%. Conclusions: The standardized incidence and death rates of pancreatic cancer in China increase year by year with an increasing trend for the burden of disease. The disease burden of pancreatic cancer is expected to rise due to the increase and aging of the population. Preventive measures should be adopted to decrease the burden of the pancreatic cancer.
Asia/epidemiology*
;
Global Burden of Disease
;
Humans
;
Incidence
;
Pancreatic Neoplasms/epidemiology*
;
Risk Factors
2.Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?
Liang WANG ; Gang LI ; Yun-Tao BING ; Mao-Lin TIAN ; Hang-Yan WANG ; Chun-Hui YUAN ; Dian-Rong XIU
Chinese Medical Sciences Journal 2021;36(4):284-294
Objective To investigate the impact of prior non-pancreatic cancer on the survival outcomes of patients with localized pancreatic neuroendocrine tumors (PanNETs). Methods We reviewed the Surveillance, Epidemiology, and End Results database and selected patients with localized PanNETs diagnosed between 1973 and 2015. We divided the patients into two groups according to the presence or absence of prior non-pancreatic malignancy. Before and after propensity score matching, we compared the clinicopathological characteristics and studied the overall survival and cancer-specific survival. Results A total of 357 (12.9%) of 2778 patients with localized PanNETs had prior cancer. A total of 1211 cases with only a localized PanNET and 133 cases with a localized PanNET and prior cancer had complete data and met the inclusion criteria of the current study. Patients with prior cancer were associated with advanced age (>65 years, 57.9% prior cancer
Aged
;
Female
;
Humans
;
Male
;
Multivariate Analysis
;
Neoplasms, Second Primary
;
Neuroendocrine Tumors/epidemiology*
;
Pancreatic Neoplasms/epidemiology*
;
Propensity Score
3.Association between Alzheimer's Disease and Cancer Risk in South Korea: an 11-year Nationwide Population-Based Study.
Ji Eun LEE ; DongWook KIM ; Jun Hong LEE
Dementia and Neurocognitive Disorders 2018;17(4):137-147
BACKGROUND AND PURPOSE: Previous studies have suggested a decreased cancer risk among patients with Alzheimer's disease (AD). There remains a lack of data on the specific types of cancer and risk factors for developing cancer in AD. We evaluated the association between AD and cancer risk, and we examined specific types of cancer. METHODS: A population-based longitudinal study was conducted using the National Health Insurance Service-Senior cohort for 2002–2013. A total of 4,408 AD patients were included in the study, as were 19,150 matched controls. Potential associations between the risk of cancer and AD were analyzed using Cox proportional hazard regressions. RESULTS: Cancer developed in 12.3% of the AD group patients and in 18.5% of control group subjects. AD was associated with a reduced risk of cancer (hazard ratio [HR], 0.70; 95% confidence intervals, 0.64–0.78). The risk of head and neck cancers was significantly reduced (HR, 0.49), as were risks for cancers of the digestive tract, including stomach cancer (HR, 0.42), colorectal cancer (HR, 0.61), liver and biliary tract cancers (HR, 0.68), and pancreatic cancer (HR, 0.55). Lung and prostate cancer risks were also significantly lower for the AD group (HR, 0.52 and HR, 0.72, respectively). CONCLUSIONS: Our results showed an inverse association between AD and cancer. Further research involving a large number of patients in a hospital based-study is needed to address the biological associations between cancer development and dementia, including AD.
Alzheimer Disease*
;
Biliary Tract Neoplasms
;
Cohort Studies
;
Colorectal Neoplasms
;
Dementia
;
Epidemiology
;
Gastrointestinal Tract
;
Head
;
Humans
;
Korea*
;
Liver
;
Longitudinal Studies
;
Lung
;
National Health Programs
;
Neck
;
Pancreatic Neoplasms
;
Prostatic Neoplasms
;
Risk Factors
;
Stomach Neoplasms
4.Type 2 Diabetes Mellitus and Its Association with the Risk of Pancreatic Carcinogenesis: A Review.
The Korean Journal of Gastroenterology 2016;67(4):168-177
The prevalence of diabetes mellitus (DM) and associated diseases such as cancers are substantially increasing worldwide. About 80% of the patients with pancreatic cancer have glucose metabolism alterations. This suggests an association between type 2 DM and pancreatic cancer risk and progression. There are hypotheses that show metabolic links between the diseases, due to insulin resistance, hyperglycemia, hyperinsulinemia, low grade chronic inflammation, and alteration in the insulin-insulin-like growth factor axis. The use of diabetes medications can influence the extent of carcinogenesis of the pancreas. This study briefly reviews recent literature on investigation of metabolic link of type 2 DM, risk of carcinogenesis of the pancreas and their association, as well as the current understanding of metabolic pathways implicated in metabolism and cellular growth. The main finding of this review, although there are discrepancies, is that according to most research long-term DM does not raise the risk of pancreatic cancer. The longest duration of DM may reflect hypoinsulinemia due to treatment for hyperglycemia, but recent onset diabetes was associated with increased risk for pancreatic cancer due to hyperinsulinemia and hyperglycemia. In conclusion, the review demonstrates that type 2 DM and the duration of diabetes pose a risk for pancreatic carcinogenesis, and that there is biological link between the diseases.
Diabetes Mellitus, Type 2/complications/epidemiology/metabolism/*pathology
;
Humans
;
Hyperglycemia/pathology
;
Insulin/metabolism
;
Insulin Resistance
;
Insulin-Like Growth Factor I/metabolism
;
Pancreatic Neoplasms/epidemiology/*etiology
;
Risk Factors
5.The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
Sunil AMIN ; Paolo BOFFETTA ; Aimee L LUCAS
Gut and Liver 2016;10(5):665-671
Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.
Adenocarcinoma
;
Aspirin
;
Dipeptidyl-Peptidase IV Inhibitors
;
Diphosphonates
;
Epidemiology
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Metformin
;
Pancreas
;
Pancreatic Neoplasms*
6.News Portrayal of Cancer: Content Analysis of Threat and Efficacy by Cancer Type and Comparison with Incidence and Mortality in Korea.
Minsun SHIM ; Yong Chan KIM ; Su Yeon KYE ; Keeho PARK
Journal of Korean Medical Science 2016;31(8):1231-1238
How the news media cover cancer may have profound significance for cancer prevention and control; however, little is known about the actual content of cancer news coverage in Korea. This research thus aimed to examine news portrayal of specific cancer types with respect to threat and efficacy, and to investigate whether news portrayal corresponds to actual cancer statistics. A content analysis of 1,138 cancer news stories was conducted, using a representative sample from 23 news outlets (television, newspapers, and other news media) in Korea over a 5-year period from 2008 to 2012. Cancer incidence and mortality rates were obtained from the Korean Statistical Information Service. Results suggest that threat was most prominent in news stories on pancreatic cancer (with 87% of the articles containing threat information with specific details), followed by liver (80%) and lung cancers (70%), and least in stomach cancer (41%). Efficacy information with details was conveyed most often in articles on colorectal (54%), skin (54%), and liver (50%) cancers, and least in thyroid cancer (17%). In terms of discrepancies between news portrayal and actual statistics, the threat of pancreatic and liver cancers was overreported, whereas the threat of stomach and prostate cancers was underreported. Efficacy information regarding cervical and colorectal cancers was overrepresented in the news relative to cancer statistics; efficacy of lung and thyroid cancers was underreported. Findings provide important implications for medical professionals to understand news information about particular cancers as a basis for public (mis)perception, and to communicate effectively about cancer risk with the public and patients.
Communication
;
Humans
;
Incidence
;
Internet/statistics & numerical data
;
Liver Neoplasms/epidemiology
;
Male
;
Mass Media/*statistics & numerical data
;
Neoplasms/*epidemiology/mortality/prevention & control
;
Pancreatic Neoplasms/epidemiology
;
Prostatic Neoplasms/epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Stomach Neoplasms/epidemiology
7.News Portrayal of Cancer: Content Analysis of Threat and Efficacy by Cancer Type and Comparison with Incidence and Mortality in Korea.
Minsun SHIM ; Yong Chan KIM ; Su Yeon KYE ; Keeho PARK
Journal of Korean Medical Science 2016;31(8):1231-1238
How the news media cover cancer may have profound significance for cancer prevention and control; however, little is known about the actual content of cancer news coverage in Korea. This research thus aimed to examine news portrayal of specific cancer types with respect to threat and efficacy, and to investigate whether news portrayal corresponds to actual cancer statistics. A content analysis of 1,138 cancer news stories was conducted, using a representative sample from 23 news outlets (television, newspapers, and other news media) in Korea over a 5-year period from 2008 to 2012. Cancer incidence and mortality rates were obtained from the Korean Statistical Information Service. Results suggest that threat was most prominent in news stories on pancreatic cancer (with 87% of the articles containing threat information with specific details), followed by liver (80%) and lung cancers (70%), and least in stomach cancer (41%). Efficacy information with details was conveyed most often in articles on colorectal (54%), skin (54%), and liver (50%) cancers, and least in thyroid cancer (17%). In terms of discrepancies between news portrayal and actual statistics, the threat of pancreatic and liver cancers was overreported, whereas the threat of stomach and prostate cancers was underreported. Efficacy information regarding cervical and colorectal cancers was overrepresented in the news relative to cancer statistics; efficacy of lung and thyroid cancers was underreported. Findings provide important implications for medical professionals to understand news information about particular cancers as a basis for public (mis)perception, and to communicate effectively about cancer risk with the public and patients.
Communication
;
Humans
;
Incidence
;
Internet/statistics & numerical data
;
Liver Neoplasms/epidemiology
;
Male
;
Mass Media/*statistics & numerical data
;
Neoplasms/*epidemiology/mortality/prevention & control
;
Pancreatic Neoplasms/epidemiology
;
Prostatic Neoplasms/epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Stomach Neoplasms/epidemiology
8.Comparison of methods of extracting information for meta-analysis of observational studies in nutritional epidemiology.
Epidemiology and Health 2016;38(1):e2016003-
OBJECTIVES: A common method for conducting a quantitative systematic review (QSR) for observational studies related to nutritional epidemiology is the "highest versus lowest intake" method (HLM), in which only the information concerning the effect size (ES) of the highest category of a food item is collected on the basis of its lowest category. However, in the interval collapsing method (ICM), a method suggested to enable a maximum utilization of all available information, the ES information is collected by collapsing all categories into a single category. This study aimed to compare the ES and summary effect size (SES) between the HLM and ICM. METHODS: A QSR for evaluating the citrus fruit intake and risk of pancreatic cancer and calculating the SES by using the HLM was selected. The ES and SES were estimated by performing a meta-analysis using the fixed-effect model. The directionality and statistical significance of the ES and SES were used as criteria for determining the concordance between the HLM and ICM outcomes. RESULTS: No significant differences were observed in the directionality of SES extracted by using the HLM or ICM. The application of the ICM, which uses a broader information base, yielded more-consistent ES and SES, and narrower confidence intervals than the HLM. CONCLUSIONS: The ICM is advantageous over the HLM owing to its higher statistical accuracy in extracting information for QSR on nutritional epidemiology. The application of the ICM should hence be recommended for future studies.
Citrus
;
Epidemiology*
;
Methods*
;
Nutrition Assessment
;
Pancreatic Neoplasms
;
Population Characteristics
9.Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions.
Gut and Liver 2015;9(5):571-589
Cystic neoplasms of the pancreas are found with increasing prevalence, especially in elderly asymptomatic individuals. Although the overall risk of malignancy is very low, the presence of these pancreatic cysts is associated with a large degree of anxiety and further medical investigation due to concerns about malignancy. This review discusses the different cystic neoplasms of the pancreas and reports diagnostic strategies based on clinical features and imaging data. Surgical and nonsurgical management of the most common cystic neoplasms, based on the recently revised Sendai guidelines, is also discussed, with special reference to intraductal papillary mucinous neoplasm (IPMN; particularly the branch duct variant), which is the lesion most frequently identified incidentally. IPMN pathology, its risk for development into pancreatic ductal adenocarcinoma, the pros and cons of current guidelines for management, and the potential role of endoscopic ultrasound in determining cancer risk are discussed. Finally, surgical treatment, strategies for surveillance of pancreatic cysts, and possible future directions are discussed.
Carcinoma, Pancreatic Ductal/epidemiology/pathology/*surgery
;
Cystadenoma/epidemiology/pathology/*surgery
;
Early Detection of Cancer/methods
;
Endosonography
;
Humans
;
Pancreatic Cyst/epidemiology/*pathology/surgery
;
Pancreatic Neoplasms/epidemiology/*pathology/surgery
;
Practice Guidelines as Topic
;
Prevalence
10.Elevated Hemoglobin A1c Levels Are Associated with Worse Survival in Advanced Pancreatic Cancer Patients with Diabetes.
Young Koog CHEON ; Ja Kyung KOO ; Yoon Serk LEE ; Tae Yoon LEE ; Chan Sup SHIM
Gut and Liver 2014;8(2):205-214
BACKGROUND/AIMS: Pre-existing diabetes mellitus (DM) has been identified as an adverse prognostic variable associated with increased mortality in various cancers. Although DM and hyperglycemia are considered risk factors for pancreatic cancer (PC), antidiabetic treatments for patients with advanced PC have been overlooked. This study aimed to evaluate the impact of hemoglobin A1c (HbA1c) levels on PC survival. METHODS: We retrospectively reviewed the medical records of first-diagnosed patients with advanced PC who were admitted to Konkuk University Medical Center from 2005 to 2011. RESULTS: A total of 127 patients were enrolled, and there were 111 deaths (87.4%) within the 7-year observational period. The most common etiology was disease progression (n=108). DM before PC diagnosis was observed in 65 patients (51.1%), including 28 patients with new-onset DM. The overall median survival times in patients with and without DM were 198 and 263 days, respectively (p=0.091). Survival time according to HbA1c was significantly different between the <7.0% and > or =7.0% groups (362 and 144 days, respectively; p=0.038). In the HbA1c > or =7.0% group, the median overall survival time was 273 days for the metformin group and 145 days for the nonmetformin oral agent group; however, there was no significant difference between the two groups (p=0.058). CONCLUSIONS: A high HbA1c level may be associated with worse survival in patients with advanced PC with DM. Antidiabetic treatment, metformin in particular, was associated with an improved outcome.
Adult
;
Aged
;
Aged, 80 and over
;
Diabetes Complications/*blood/complications/*mortality
;
Female
;
Hemoglobin A, Glycosylated/*metabolism
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Pancreatic Neoplasms/*blood/complications/*mortality
;
Prognosis
;
Republic of Korea/epidemiology
;
Retrospective Studies

Result Analysis
Print
Save
E-mail